| Code | CSB-RA618886MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to HLX-60, targeting LRRC32 (Leucine Rich Repeat Containing 32), also known as GARP (Glycoprotein A Repetitions Predominant). LRRC32 is a cell surface docking receptor that plays a critical role in the activation and presentation of latent TGF-β, particularly on regulatory T cells (Tregs) and activated platelets. By anchoring latent TGF-β to the cell surface, LRRC32 facilitates local immunosuppression and maintains immune homeostasis. Dysregulation of LRRC32 expression has been implicated in various pathological conditions, including cancer immune evasion, fibrotic diseases, and autoimmune disorders, making it an important target for immunological research.
HLX-60 represents a therapeutic antibody designed to block LRRC32-mediated TGF-β activation, potentially reversing tumor-associated immunosuppression. This biosimilar antibody serves as a valuable research tool for investigating LRRC32 biology, TGF-β signaling pathways, Treg function, and tumor microenvironment dynamics. It enables researchers to explore mechanisms of immune regulation and evaluate potential therapeutic strategies targeting the LRRC32-TGF-β axis in oncology and immunology studies.
There are currently no reviews for this product.